On August 29, 2018 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it will participate in two panel discussions, at the 2018 Citi Biotech Conference in Boston. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will represent Mirati at the event (Press release, Mirati, AUG 29, 2018, View Source [SID1234529138]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Targeted Therapies Oncology – Aiming for the Bull’s Eye" Panel on Wednesday, September 5th at 3:15 p.m. ET/12:15 p.m. PT

"Landscape in Immuno-Oncology and Bi-Specific Antibodies" Panel on Thursday, September 6th at 9:00 a.m. ET/ 6:00 a.m. PT

The webcasts will be available through the "Investors" section of www.mirati.com, and a replay of the webcasts will be made available for 90 days following the event.